glp 1 gip gcg GLP-1, and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy The data just dropped —

Doctors and patients alike are increasingly exploring how fractional doses can target specific metabolic and inflammatory issues without the intensity of a full weight-loss regimen

Overall, the focus needs to be on macronutrients protein especially and some form of exercise

Patients on stable blood pressure regimens who begin semaglutide therapy should expect their healthcare provider to monitor readings more frequently, typically every 2 to 4 weeks initially, to assess whether medication adjustments become necessary

By addressing multiple health burdens with a single therapy, GLP1s are reshaping how providers think about chronic disease management

Some plans may cover FDA-approved medications, such as Wegovy (semaglutide) or Zepbound (tirzepatide), but they often require prior authorization or proof of medical necessity

Patients can administer the medication into the abdomen or upper thighs using the injector pen